Vivalytic | All In One Molecular Solution
–
Molecular Diagnostics at the Point of Care
Why Choose the Vivalytic?
- Fully automated, sample to answer point of care diagnostics
- Full molecular workflow consolidated into one small benchtop platform
- Unique test menu covering a diverse range of respiratory, genitourinary and hospital acquired infections including SARS-CoV-2 (COVID-19)
- Hi-Plex & Lo-Plex Capabilities. Powered by Randox Biochip Technology enabling multiple results from one patient sample
- Wireless connectivity, no peripherals required making Vivalytic a unique space-saving & hygienic solution
- Easy 4 step process from sample entry to results. No laboratory training required
The Vivalytic platform is a universal, fully automated all in one solution for molecular diagnostics. It is a cartridge-based platform enabling Hi-Plex and Lo-Plex testing developed in partnership with Bosch. Vivalytic consolidates the full molecular workflow into a small benchtop platform, capable of extraction, PCR amplification and detection. Randox multiplex Biochip Technology powers Vivalytic enabling multiple results from one patient sample. Randox patented Biochip Technology allows simultaneous detection of multiple targets from a single patient sample. The biochip detection system is based on a chemiluminescent signal, this is the emission of light, without heat, as a result of a chemical reaction. Each biochip is prefabricated with spatially discrete testing regions (DTR’s). Each DTR represents an individual test. Each DTR can be occupied with oligonucleotides specific to a pathogen or target of interest. The Hi-Plex capabilities of Biochip Technology eliminates the need to run multiple time consuming and sample intensive assays.
Vivalytic Test Menu
| VIRUSES | ||
| SARS-CoV-2 (COVID-19) | ||
| VIRUSES | ||
| SARS-CoV-2 (COVID-19) | ||
| VIRUSES | |
| SARS-CoV-2 (COVID-19) | Sarbecovirus (SARS, SARS like, SARS-CoV-2) |
| VIRUSES | ||
| SARS-CoV-2 (COVID-19) | Sarbecovirus (SARS, SARS like, SARS-CoV-2) | Influenza A |
| Coronavirus 229E/NL63 | Adenovirus A/B/C/D/E | Influenza B |
| Coronavirus OC43/HKUI | Enterovirus A/B/C | Rhinovirus A/B |
| Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | ||
| VIRUSES | ||
| Adenovirus | Respiratory syncytial virus B | Influenza B |
| Metapneumovirus | Rhinovirus A/B/C | |
| Respiratory syncytial virus A | Influenza virus A | |
| BACTERIA | ||
| Achromobacter xylosoxidans | Moraxella catarrhalis | Pseudomonas aeruginosa |
| Bordetella pertussis | Mycoplasma pneumoniae | Staphylococcus aureus |
| Burkholderia cepacia complex (21 spp) | Non-tuberculous mycobacterium (15 spp | Stenotrophomonas maltophila |
| Burkholderia Cenocepacia | Mycobacterium abscessus subgroup (4 spp) | Streptococcus pneumoniae (21spp) |
| Burkholderia multivorans | Mycobacterium avium complex (4 spp) | Streptococcus species (19 spp) |
| Chlamydia pneumoniae | Pandoraea species (5spp) | Veillonella species (3 spp) |
| Haemophilus influenza | Prevotella species (16 spp) | |
| FUNGI | ||
| Aspergillus fumigatus | Candida albicans | Exophialia dermatitidis |
| Scedosporium species (7 spp) | ||
| ANTIBIOTIC RESISTANCE MARKERS | ||
| mecA (incl MRSA) | ||
| BACTERIA | ||
| Methicillin-resistant Staphylococcus aureus (MRSA) | Methicillin-sensitive Staphylococcus aureus (MSSA) | Methicillin-resistant coagulase-negative Staphylococci (MRCoNS) |
| VIRUSES | ||
| Influenza A | Coronavirus OC43/HKUI | Parainfluenza virus 3 |
| Influenza B | Enterovirus A/B/C | Parainfluenza virus 4 |
| Adenovirus A/B/C/D/E | Metapneumovirus | Respiratory syncytial virus A/B |
| Bocavirus 1/2/3 | Parainfluenza virus 1 | Rhinovirus A/B/C |
| Coronavirus 229E/NL63 | Parainfluenza virus 2 | |
| BACTERIA | ||
| Bordetella parapertussis | Haemophilus influenzae | Mycoplasma pneumoniae |
| Bordetella pertussis | Legionella pneumophila | Streptococcus pneumoniae |
| Chlamydophila pneumoniae | Moraxella catarrhalis | |
| VIRUSES | ||
| Influenza A | Influenza B | Respiratory Syncytial Virus (RSV) |
| VIRUSES | |
| Neisseria Gonorrhoeae (NG) | Haemophilus Ducreyi (HD) |
| Mycoplasma Genitalium (MG) | Mycoplasma Hominis (MH) |
| Ureaplasma Urealyticum (UU) | Treponema Pallidum (TP) |
| Chlamydia Trachomatis (CT) | Herpes Simplex virus 1(HSV-1) |
| Trichomonas Vaginalis (TV) | Herpes Simplex virus 2(HSV-2) |
| BACTERIA | ||
| Citrobacter freundii | Klebsiella oxytoca | Serratia marcescens |
| Citrobacter koseri | Klebsiella pneumoniae | Staphylococcus aureus |
| Klebsiella aerogenes | Morganella morganii | Staphylococcus epidermidis |
| Enterobacter cloacae | Proteus spp. | Staphylococcus saprophyticus |
| Enterococcus faecalis | Pseudomonas aeruginosa | Streptococcus agalactiae (GBS) |
| Enterococcus faecium | Providencia rettgeri | |
| FUNGUS | ||
| Candida albicans | ||
| ANTIOBIOTIC RESISTANCE MARKERS | ||
| mecA (incl MRSA) | Trimethoprim Resistance 3 | Van A (Vancomycin Resistance A) |
| Trimethoprim Resistance 1 | Trimethoprim Resistance 4 | Van B (Vancomycin Resistance B) |
| Trimethoprim Resistance 2 | Trimethoprim Resistance 5 | |
Vivalytic Workflow
Intuitive engineering of Vivalytic ensures the analyser is user friendly. The process of patient sample to result comprises a very simple 4 step workflow.
To begin the test, the user scans or enters sample information. The cartridge code is then scanned into the embedded Vivalytic software. The user then adds sample into the dedicated cartridge slot, closes the lid and inserts the cartridge into the Vivalytic.
The touchscreen display will countdown the time remaining to test completion. Results will be displayed on the screen. Multiple Vivalytics can be wirelessly connected allowing the user to control multiple tests at one time all reporting to a master Vivalytic platform.
“AWARD-WINNING DESIGN DELIVERS
AN UNCOMPLICATED USER EXPERIENCE”
Want to know more?
Contact us or visit our COVID-19 Monitoring & Management page
Related Products
